Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238911 · ClinicalTrials.gov registry record · Phase 3
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
A Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
- 16
- Study locations
NCT03238911 is a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia that has completed, run by Pharmacosmos A/S. The registered enrollment target is 123 participants, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (35% lower). The trial reports 16 study locations across 9 states.
The verdict
NCT03238911, a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
- 16
- Study locations
Study Summary
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
Conditions Studied
Interventions
- DRUG Ferric carboxymaltose
- DRUG Iron isomaltoside/ferric derisomaltose
Study Locations (16)
Florida
- Pharmacosmos Investigational Site - Clearwater
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site 1 - Miami
- Pharmacosmos Investigational Site 2 - Miami
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site - Miami
California
- Pharmacosmos Investigational Site - Los Angeles
- Pharmacosmos Investigational Site - Sacramento
- Pharmacosmos Investigational Site - Santa Ana
Indiana
- Pharmacosmos Investigational Site - Indianapolis
Kansas
- Pharmacosmos Investigational Site - Wichita
Louisiana
- Pharmacosmos Investigational Site - Metairie
Pennsylvania
- Pharmacosmos Investigational Site - Lancaster
Texas
- Pharmacosmos Investigational Site - Houston
Utah
- Pharmacosmos Investigational Site - Orem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2018-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03238911
The ClinicalTrials.gov registry entry for NCT03238911 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (35% lower). The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 2 interventions - of which Ferric carboxymaltose is the first listed.
NCT03238911 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT03238911 about?
NCT03238911 is a clinical study titled "Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia". The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
What is the current status of trial NCT03238911?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2017-10-24. Estimated completion is 2018-06-19.
What conditions does trial NCT03238911 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia.
What interventions are being tested in trial NCT03238911?
The interventions under investigation include: Ferric carboxymaltose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT03238911?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03238911 being conducted?
This trial has 16 study locations across California, Florida, Indiana, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
-
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.